Closing the Epilepsy Treatment Gap:
Old Challenges, New Opportunities
Featuring:
Dr. Fedor Panov and Dr. Patrick Landazuri
Sunday, December 4 from 6:00-9:00pm CT
Advanced Neuromodulation Technology & Post‑Fellowship Advice
Featuring:
Dr. Danielle Becker and Dr. Deepak Madhavan
Friday, December 2 from 6:00-8:00pm CT
Get hands-on RNS System programming training and learn how Simple Set Programming can streamline your clinic experience.
Saturday, December 3 – Monday, December 5th (60 ‑ 90 minutes)
Saturday, December 3 - Monday, December 5
Learn about all the exciting new things NeuroPace is doing to advance the treatment of epilepsy including our NAUTILUS IGE trial, the RNS System’s nearly 11 year battery life*, and Simple Set Programming.
†CAUTION—Investigational device. Limited by United States law to investigational use for the following Indications for Use: The RNS® System is intended for thalamic stimulation as an adjunctive therapy for the treatment of primary generalized seizures in individuals 12 years of age or older who have drug-resistant idiopathic generalized epilepsy.
*The median battery longevity is 10.8 years, on average, for the RNS Neurostimulator (model RNS-320). Estimates for longevity were derived from medium stimulation utilization (mAh/day).
Rx Only. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci. See important prescribing and safety information at https://www.neuropace.com/safety/.
©2022 NeuroPace, Inc. All rights reserved. NeuroPace, RNS, and Window to the Brain are registered trademarks of NeuroPace, Inc. NP 220137 Rev 2 / Rev date: 2022-11
© 2024 NeuroPace, Inc..
